85 related articles for article (PubMed ID: 22910440)
61. Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.
Li CH; Bies RR; Wang Y; Sharma MR; Karovic S; Werk L; Edelman MJ; Miller AA; Vokes EE; Oto A; Ratain MJ; Schwartz LH; Maitland ML
Clin Transl Sci; 2016 Feb; 9(1):43-50. PubMed ID: 26790562
[TBL] [Abstract][Full Text] [Related]
62. Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.
Buil-Bruna N; López-Picazo JM; Martín-Algarra S; Trocóniz IF
Oncologist; 2016 Feb; 21(2):220-32. PubMed ID: 26668254
[TBL] [Abstract][Full Text] [Related]
63. Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression.
Zhu M; Tang R; Doshi S; Oliner KS; Dubey S; Jiang Y; Donehower RC; Iveson T; Loh EY; Zhang Y
Br J Cancer; 2015 Feb; 112(3):429-37. PubMed ID: 25584489
[TBL] [Abstract][Full Text] [Related]
64. Model-based clinical drug development in the past, present and future: a commentary.
Kimko H; Pinheiro J
Br J Clin Pharmacol; 2015 Jan; 79(1):108-16. PubMed ID: 24527997
[TBL] [Abstract][Full Text] [Related]
65. Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.
Bender BC; Schindler E; Friberg LE
Br J Clin Pharmacol; 2015 Jan; 79(1):56-71. PubMed ID: 24134068
[TBL] [Abstract][Full Text] [Related]
66. Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer.
Bruno R; Lindbom L; Schaedeli Stark F; Chanu P; Gilberg F; Frey N; Claret L
CPT Pharmacometrics Syst Pharmacol; 2012 Dec; 1(12):e19. PubMed ID: 23835839
[TBL] [Abstract][Full Text] [Related]
67. Estimation of renal cell carcinoma treatment effects from disease progression modeling.
Maitland ML; Wu K; Sharma MR; Jin Y; Kang SP; Stadler WM; Karrison TG; Ratain MJ; Bies RR
Clin Pharmacol Ther; 2013 Apr; 93(4):345-51. PubMed ID: 23443753
[TBL] [Abstract][Full Text] [Related]
68. Modeling NSCLC progression: recent advances and opportunities available.
Suleiman AA; Nogova L; Fuhr U
AAPS J; 2013 Apr; 15(2):542-50. PubMed ID: 23404126
[TBL] [Abstract][Full Text] [Related]
69. Improving lung cancer survival; time to move on.
Heuvers ME; Hegmans JP; Stricker BH; Aerts JG
BMC Pulm Med; 2012 Dec; 12():77. PubMed ID: 23234250
[TBL] [Abstract][Full Text] [Related]
70. Models of excellence: improving oncology drug development.
Sharma MR; Maitland ML; Ratain MJ
Clin Pharmacol Ther; 2012 Nov; 92(5):548-50. PubMed ID: 23085878
[TBL] [Abstract][Full Text] [Related]
71. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
72. Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Boccardo F; Grossi F
Expert Opin Pharmacother; 2014 Aug; 15(12):1771-80. PubMed ID: 25032887
[TBL] [Abstract][Full Text] [Related]
73. Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.
Claret L; Lu JF; Bruno R; Hsu CP; Hei YJ; Sun YN
Clin Pharmacol Ther; 2012 Nov; 92(5):631-4. PubMed ID: 22910440
[TBL] [Abstract][Full Text] [Related]
74. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR
J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922
[TBL] [Abstract][Full Text] [Related]
75. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
Blumenschein GR; Kabbinavar F; Menon H; Mok TSK; Stephenson J; Beck JT; Lakshmaiah K; Reckamp K; Hei YJ; Kracht K; Sun YN; Sikorski R; Schwartzberg L;
Ann Oncol; 2011 Sep; 22(9):2057-2067. PubMed ID: 21321086
[TBL] [Abstract][Full Text] [Related]
76. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Kubota K; Yoshioka H; Oshita F; Hida T; Yoh K; Hayashi H; Kato T; Kaneda H; Yamada K; Tanaka H; Ichinose Y; Park K; Cho EK; Lee KH; Lin CB; Yang JC; Hara K; Asato T; Nakagawa K
J Clin Oncol; 2017 Nov; 35(32):3662-3670. PubMed ID: 28902534
[TBL] [Abstract][Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
